In contrast, the effect estimates for HMGCR inhibitionwere all statistically significant for all aortic diseases and CAVS, indicating areduced risk: HMGCR inhibition and AAA (OR: 0.202, 95% CI:0.107–0.315, p< 0.0055), HMGCR inhibition and TAA (OR:0.556, 95% CI: 0.372–0.831, p< 0.0055), HMGCR inhibitionand AD (OR: 0.217, 95% CI: 0.0.98–0.480, p< 0.0055), HMGCRinhibition and CAVS (OR:0.554, 95% CI: 0.433–0.707, p< 0.0055). Here, HMGCR is linked to triple-A syndrome.